Egret Therapeeutics I, a series of Capitalize Investments LLC

Tommarello operating as sole named GP with a 06b exemption (pre-existing relationships only) signals a closed network raise targeting existing LPs or direct relationships rather than an open market strategy, typical of emerging managers or those building a strategy within a larger sponsor platform.

A mid-2026 filing in the therapeutics space aligns with LP rebalancing cycles and potential portfolio construction around biotech/life sciences allocations, though the $0M target and absence of manager track record on file raise questions about whether this is a substantive raise or a strategic placeholder ahead of a defined commitment period.

Before engaging, verify whether this filing will be updated with a non-zero target amount and whether there is a key-man provision around Tommarello; also confirm the relationship between Capitalize Investments LLC and any other operating entities or parallel vehicles that may be raising capital for overlapping therapeutics strategies.